Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. … Read more
Paradigm Biopharmaceuticals Limited (PBIGF) - Total Liabilities
Latest total liabilities as of June 2025: $3.39 Million USD
Based on the latest financial reports, Paradigm Biopharmaceuticals Limited (PBIGF) has total liabilities worth $3.39 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Paradigm Biopharmaceuticals Limited - Total Liabilities Trend (2014–2025)
This chart illustrates how Paradigm Biopharmaceuticals Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Paradigm Biopharmaceuticals Limited Competitors by Total Liabilities
The table below lists competitors of Paradigm Biopharmaceuticals Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Husteel
KO:005010
|
Korea | ₩316.81 Billion |
|
Japan Display Inc
PINK:JNNDF
|
USA | $144.72 Billion |
|
A Plus Asset Advisor Co Ltd
KO:244920
|
Korea | ₩242.32 Billion |
|
Dimand S.A.
AT:DIMAND
|
Greece | €114.01 Million |
|
Nexity SA
PINK:NNXXY
|
USA | $4.04 Billion |
|
Sunflag Iron And Steel Company Limited
NSE:SUNFLAG
|
India | ₹23.28 Billion |
|
South Atlantic Bancshares Inc
OTCQX:SABK
|
USA | $1.79 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Paradigm Biopharmaceuticals Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Paradigm Biopharmaceuticals Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Paradigm Biopharmaceuticals Limited (2014–2025)
The table below shows the annual total liabilities of Paradigm Biopharmaceuticals Limited from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $3.39 Million | -5.49% |
| 2024-06-30 | $3.58 Million | -73.23% |
| 2023-06-30 | $13.39 Million | +59.88% |
| 2022-06-30 | $8.38 Million | +28.49% |
| 2021-06-30 | $6.52 Million | +55.88% |
| 2020-06-30 | $4.18 Million | +54.62% |
| 2019-06-30 | $2.70 Million | +103.80% |
| 2018-06-30 | $1.33 Million | +38.92% |
| 2017-06-30 | $955.29K | -14.45% |
| 2016-06-30 | $1.12 Million | +93.42% |
| 2015-06-30 | $577.33K | +56.60% |
| 2014-06-30 | $368.67K | -- |